Skip to content

Trial · Interventional

CompletedPhase 2Results postedRegistry data

A Study of Oxytocin in Children and Adolescents With Autistic Disorder

Short name Oxytocin

Overview

Status
Completed
Phase
Phase 2
Enrollment
25 participants (actual)
Sponsor
University of North Carolina, Chapel Hill · Other
Design
Randomized · Quadruple masking
Countries
1 country

United States

Start
Mar 2011
Primary completion
Apr 2013
Completion
Apr 2013
First posted
4 Mar 2011 (estimated)
Last update posted
17 Jul 2017
Conditions
Autism

Timeline

1 trial · 1 completed · 1 with posted results

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2011201220132014
  1. Ph 2

    Oxytocin

    NCT01308749

    Mar 2011 to Apr 2013

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The investigators propose to conduct this pilot study to evaluate oxytocin as a supplemental treatment for improving social difficulties in individuals with autism.

Interventions

  • OxytocinDrug
  • PlaceboDrug

Arms2

  • Placebo comparator

    Placebo

    Intervention: Drug: placebo

  • Active comparator

    Oxytocin

    Intervention: Drug: Syntocinon® Nasal Spray

Primary outcomes2

Outcomes the sponsor listed as primary.

  1. Number of Participants Who Could Tolerate Twice Daily Oxytocin

    Time frame · Week 0 to week 8

    Registry description

    This study will help to determine tolerability of intranasal oxytocin treatment in children with autism by measuring the ability of at least 80% of the sample to tolerate twice daily intranasal administration of oxytocin.

  2. Number of Participants Who Could Tolerate Twice Daily Oxytocin

    Time frame · Week 0 to week 16

    Registry description

    This study will help to determine tolerability of intranasal oxytocin treatment in children with autism by measuring the ability of at least 80% of the sample to tolerate twice daily intranasal administration of oxytocin.

Secondary outcomes(9)
  1. Change in Mean Plasma Oxytocin Level During Period 1 - Double Blind Phase

    Time frame · Week 0 to week 8

    Registry description

    Blood samples will be collected to obtain proof of concept data regarding changes in afternoon plasma oxytocin levels

  2. Change in Mean Weight

    Time frame · between weeks 0 and 8

    Registry description

    changes during period 1

  3. Change in Mean Total Social Social Responsiveness Scale (SRS) T-score

    Time frame · 0-8 weeks, blinded treatment, period 1

    Registry description

    The 65-item SRS is a standardized measure of the core symptoms of autism. Each item is scored on a 4-point Likert scale. The raw score of each individual item is summed to create a total raw score. The total raw score is then translated into a total T-scores (which are the equivalent of standard scores). Total T-scores results are as follows: 59 and below: within normal limits, 60-65: Mild range of impairment 66-75: Moderate range of impairment 76 or higher: Severe range of impairment.

  4. Change in Mean Autism Diagnostic Observation Schedule (ADOS) Total Score

    Time frame · Baseline to 16 Weeks

    Registry description

    The ADOS is a semi-structured assessment used to assess and diagnose individuals suspected of having autism of varying ages, developmental levels, and language skills (from no speech to verbally fluent). The ADOS includes four modules, each requiring just 35-40 minutes to administer. The individual being evaluated is given just one of 4 modules, depending on his or her expressive language level and chronological age. The rater will observe social and communication behaviors during various activities in the appropriate module. A rater then uses a 0-3 scale to rate each type of behavior. A select number of individual items will be summed for a total score representing communication and reciprocal social interaction. In scoring all 3's are collapsed to a 2. A higher score indicates more severe impairment. Ranges of scores are as follows: Module 1: 0-24, Module 2: 0-24, Module 3: 0-22, Module 4: 0-22.

  5. Change in Mean Aberrant Behavior Checklist (ABC)-Social Withdrawal Subscale Score Over Both Periods

    Time frame · Baseline to 16 Weeks

    Registry description

    Efficacy measures included the Aberrant Behavior Checklist -Social Withdrawal subscale scor. The ABC which focuses on problem behaviors in five subdomains, including irritability, attention, repetitive behaviors, unusual speech, and lethargy. A modified version of the lethargy subscale was used. Typically the Lethargy subscale includes 16 items, however, for our purposes 3 items that were specifically related to lethargy (i.e.: listlessness) were removed so that the focus could primarily be on aberrant social behavior. Differences in only the Social Withdrawal domain were assessed.The is the sum of items, each rated among 0 = Not at all; 1 = Slight in degree; 2 = Moderately serious; and 3 = Severe in degree. The ABC- Social Withdrawal total score ranges from 0 to 39. Higher values represent greater severity of illness.

  6. Change in Mean Pervasive Developmental Disorder Behavior Inventory - Screening Version (PDDBI-SV) Total Score Over Both Periods

    Time frame · Baseline to 16 Weeks

    Registry description

    The PDDBI-SV examines both adaptive and maladaptive behaviors related to autism. It has normative scores for children between 2-11 years. For children 12 years and older, the norms (11 years, 11 months) will be used. Each item is scored on a scale from 0-3. For the first 9 items, the total of individual items is summed. For items 10-18, the scores are reversed and then summed (i.e.: 0=3, 1 =2, 2=2, 3 = 0). Then the total of 0-9 and then the reversed scored items 10-18 are summed for a final total score. Higher scores indicate more impairment. The range of total scores is 0-54. ASD/Social deficits unlikely: 0-6, More information needed/borderline: 7-10, autism spectrum disorder (ASD)/social deficits likely (mild):11-14, ASD/social deficits likely (moderate): 15-29, ASD/social deficits likely (severe): 30-37, ASD/social deficits likely (extreme): 38 or higher.

  7. Change in Mean Systolic Blood Pressure During Period 1

    Time frame · Week 0 to 8

    Registry description

    Change in mean systolic blood pressure during double blind phase

  8. Mean Change in Prolactin Levels Over Period 1

    Time frame · Week 0 to 8

    Registry description

    Serum prolactin levels were collected and analyzed in participants

  9. Mean Change in Temperature During Period 1

    Time frame · Week 0 to 8

    Registry description

    Temperature was collected on each participant via oral or temporal thermometer. The mean change in each group was assessed.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

Primary outcome results

Primary outcomeCount of participants· Week 0 to week 8

Number of Participants Who Could Tolerate Twice Daily Oxytocin

GroupValue (Participants)
Sequence 2: Placebo:Oxytocin13
Sequence 1: Oxytocin:Oxytocin11
Primary outcomeCount of participants· Week 0 to week 16

Number of Participants Who Could Tolerate Twice Daily Oxytocin

GroupValue (Participants)
Sequence 2: Placebo:Oxytocin11
Sequence 2: Oxytocin:Oxytocin11
Secondary and other outcome results(6)
Secondary outcomeMean· Week 0 to week 8

Change in Mean Plasma Oxytocin Level During Period 1 - Double Blind Phase

GroupValue (picograms/mL (pg/mL))Spread
Sequence 2: Placebo:Oxytocin-0.691.69
Sequence 1: Oxytocin:Oxytocin-0.151.53
Secondary outcomeMean· between weeks 0 and 8

Change in Mean Weight

GroupValue (pounds)Spread
Sequence 1: Oxytocin-oxytocin1.41.3
Sequence 2: Placebo :Oxytocin2.40.7
Secondary outcomeMean· 0-8 weeks, blinded treatment, period 1

Change in Mean Total Social Social Responsiveness Scale (SRS) T-score

GroupValue (T-scores)Spread
Sequence 1: Oxytocin-oxytocin-5.12.3
Sequence 2: Placebo :Oxytocin-3.93.3
Secondary outcomeMean· Baseline to 16 Weeks

Change in Mean Autism Diagnostic Observation Schedule (ADOS) Total Score

GroupValue (scores on a scale)Spread
Sequence 1: Oxytocin-oxytocin-0.360.39
Sequence 2: Placebo :Oxytocin-0.310.29
Secondary outcomeMean· Baseline to 16 Weeks

Change in Mean Aberrant Behavior Checklist (ABC)-Social Withdrawal Subscale Score Over Both Periods

GroupValue (scores on a scale)Spread
Sequence 1: Oxytocin-oxytocin-3.71.0
Sequence 2: Placebo :Oxytocin-2.21.9
Secondary outcomeMean· Baseline to 16 Weeks

Change in Mean Pervasive Developmental Disorder Behavior Inventory - Screening Version (PDDBI-SV) Total Score Over Both Periods

GroupValue (scores on a scale)Spread
Sequence 1: Oxytocin-oxytocin-3.62.4
Sequence 2: Placebo :Oxytocin-3.02.2

Adverse events, as posted

Adverse events as posted: participants affected out of participants at risk, by group
GroupDeathsSerious eventsOther events
Sequence 1: Oxytocin:Oxytocin Period 1weeks 0-8Intervention: Drug: Syntocinon® Nasal Spray Oxytocin: Subjects will use the Syntocinon® Nasal Spray (oxytocin) twice daily for 8 weeks if they are randomized to that arm in the Randomized Phase. All subjects will use the Syntocinon® Nasal Spray twice daily for 8 weeks in the Open Label Phase. Subjects ages 3-10 years old will be titrated up to a maximum dose of 24IU. Subjects ages 11-17 years old will be titrated up to a maximum dose of 32IU.0 / 121 / 1212 / 12
Sequence 2: Placebo: Oxytocin Period 1 Weeks 0-8Intervention: Drug: placebo Placebo: Placebo Nasal Spray0 / 130 / 1310 / 13
Sequence 1: Oxytocin:Oxytocin Period 2, Weeks 8-16evaluates longer term adverse events with oxytocin0 / 110 / 248 / 11
Sequence 2: Placebo:Oxytocin Period 2evaluates acute exposure to oxytocin in sequence 2 participants0 / 130 / 1312 / 13

Each cell reads participants affected / participants at risk, as the registry posted them.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 3 Years up to 17 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Between 3 and 17 years old, inclusive. * Have a clinical diagnosis of autistic disorder confirmed according to Diagnostic Statistical Manual of Mental Disorders-IV criteria by using the Autism Diagnostic Interview - Revised (ADI-R) and/or the Autism Diagnostic Observation Scale (ADOS, Lord et al., 1989). Exclusion Criteria: * Changes in allied health therapies, behavioral or educational interventions within the past 2 months of the baseline visit other than those associated with school holidays. * Changes in psychotropic and alternative medication doses in the last 30 days of the baseline visit. * Subjects with a medical condition that might interfere with the conduct of the study, confound interpretation of the study results, or endanger their own well-being. This includes, but is not limited to, Rett Syndrome, impairment of renal function, evidence or history of malignancy or any significant hematological, endocrine, cardiovascular (including any rhythm disorder and uncontrolled hypertension), respiratory, hepatic, or gastrointestinal disease. * Marked sensory impairment such as deafness or blindness that would interfere with conduct of the study. * Pregnancy/Nursing because of the unknown effects of oxytocin to unborn babies and/or nursing infants. All females of child-bearing potential will be administered a urine or serum pregnancy test at screening and at any point during the study at physician discretion. Refusal to undergo a pregnancy test will result in exclusion from the study. The investigators will share results of pregnancy test with the subject's legal guardian. * Refusal to practice contraception if sexually active because the effects of exposure to high concentrations of oxytocin on sperm or newly conceived embryos are unknown. Sexually active men and women should not take part in this study if they and their partners are not both using an effective birth control method (for example, women use birth control pills, an intrauterine device (IUD) or a diaphragm and men use condoms). * Inability of caretakers to speak English. * Absence of a consistent caretaker to report on symptoms. * Subjects who, in the Investigator's opinion, might not be suitable for the study.

PepBank is a research reference. Talk to a doctor before you use any peptide.